knowledge -WSS

knowledge

author：fashion 2025-09-27 12:21:47 - browse：3155

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare drug price negotiation legal challenge met with skepticism

knowledge

leisure time

WSS

Readout Newsletter: The latest on Novavax, Merck, Bluebird

How faith leaders like me can help address America's obesity epidemic

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Deposition: Sackler embraced plan to conceal OxyContin’s strength

How faith leaders like me can help address America's obesity epidemic

'Essentially witchcraft:' A former naturopath takes on the field

hotspot

knowledge

hotspot

The high cost of giving birth even with insurance

5 takeaways from STAT's examination of Zynex Medical

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Moderna says combo Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Philips to halt sales of sleep apnea machines in U.S.

Drug repurposing or repositioning? The language matters

5 takeaways from STAT's examination of Zynex Medical

Hollywood unions extend contract negotiations for actors

Humana’s losses in Medicare Advantage tank its stock

knowledge

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Health Care Service Corp to buy Cigna Medicare Advantage plans

Syphilis numbers in the United States reach record heights

Medicare Advantage insurers face 0.2% cut to 2025 payments

Teladoc has a new CEO, but challenges remain the same

Health care court cases: Humana, Sutter, Novant

explore

knowledge

leisure time

focus